Cellectis Granted CRISPR/Cas Patents for T-Cell Modification

Business Wire, 13 February 2018, https://www.businesswire.com/news/home/20180212006461/en/Issued-U.S.-Patents-Granted-Cellectis-CRISPR-T-Cells

Cellectis has been granted patents for a T-cell genetic engineering method using transient expression of the CRISPR/Cas9 components.  A similar patent has already been issued by the European Patent Office.  This technology will be used to develop engineered CAR T-cells and the technology will be available for licensing.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply